SEC Form 4 · accession 0001209191-19-004551
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pritesh Shah
Officer — Chief Commercial Officer
Period of report
Jan 16, 2019
Accepted (ET)
Jan 18, 2019 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 16, 2019 | M | 12,500 | $11.85 | A | 29,587 | D | |
| Ordinary SharesF2 | Jan 16, 2019 | S | 12,500 | $45.003 | D | 17,087 | D | |
| Ordinary SharesF1 | Jan 16, 2019 | M | 12,500 | $19.25 | A | 29,587 | D | |
| Ordinary SharesF3 | Jan 16, 2019 | S | 12,500 | $45.003 | D | 17,087 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF4 | $11.85 | Jan 16, 2019 | M | 12,500 | D | — | May 2, 2027 | Ordinary Shares | 12,500 | 37,500 | D |
| Options to Buy Ordinary SharesF4 | $19.25 | Jan 16, 2019 | M | 12,500 | D | — | Jul 25, 2027 | Ordinary Shares | 12,500 | 37,500 | D |
Explanation of responses
- F1Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah.
- F2On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 12,500 shares in multiple trades at prices ranging from $45.00 to $45.03. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 12,500 shares in multiple trades at prices ranging from $45.00 to $45.03. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F4Options exercised were fully vested as of the date hereof.